Table 2.
Number of events by randomised intervention for each outcome
| Trial | Intervention | Patient years* | Myocardial infarction† | Stroke† | Cardiovascular death | Death‡ | APTC composite outcome |
|---|---|---|---|---|---|---|---|
| ADAPT | Placebo | 1982 | 13 | 7 | 3 | 12 | 22 |
| ADAPT | Naproxen | 1332 | 13 | 10 | 3 | 11 | 23 |
| ADAPT | Celecoxib | 1346 | 8 | 7 | 4 | 9 | 17 |
| Aisen 2003 | Placebo | 115 | 1 | 1 | 1 | 1 | 2 |
| Aisen 2003 | Naproxen | 124 | 0 | 5 | 1 | 1 | 6 |
| Aisen 2003 | Rofecoxib | 126 | 3 | 4 | 2 | 2 | 7 |
| Geusens 2004 | Placebo | 111 | 0 | 1 | 0 | 0 | 1 |
| Geusens 2004 | Naproxen | 118 | 0 | 0 | 0 | 0 | 0 |
| Geusens 2004 | Lumiracoxib | 234 | 2 | 3 | 2 | 2 | 6 |
| APC | Placebo | 1558 | 3 | 3 | 1 | 6 | 7 |
| APC | Celecoxib | 3124 | 18 | 8 | 11 | 18 | 37 |
| GAIT | Placebo | 140 | NA | NA | 0 | 0 | NA |
| GAIT | Celecoxib | 146 | NA | NA | 0 | 0 | NA |
| IQ5-97-02-001 | Placebo | 120 | 0 | 3 | 2 | 4 | 3 |
| IQ5-97-02-001 | Celecoxib | 285 | 2 | 7 | 8 | 13 | 12 |
| PreSAP | Placebo | 1570 | 4 | 7 | 4 | 7 | 12 |
| PreSAP | Celecoxib | 2331 | 9 | 9 | 4 | 11 | 21 |
| Lehmann 2005 | Placebo | 98 | 1 | 0 | 0 | 0 | 1 |
| Lehmann 2005 | Celecoxib | 99 | 0 | 0 | 0 | 0 | 0 |
| Lehmann 2005 | Lumiracoxib | 200 | 0 | 1 | 1 | 1 | 2 |
| APPROVe | Placebo | 5711 | 18 | 9 | 13 | 28 | 34 |
| APPROVe | Rofecoxib | 5658 | 34 | 19 | 16 | 36 | 59 |
| Reines 2004 | Placebo | 293 | 4 | 5 | 3 | 8 | 12 |
| Reines 2004 | Rofecoxib | 273 | 2 | 1 | 4 | 14 | 4 |
| Thal 2005 | Placebo | 1820 | 13 | 15 | 3 | 20 | 28 |
| Thal 2005 | Rofecoxib | 1599 | 22 | 7 | 13 | 41 | 33 |
| VICTOR | Placebo | 986 | 1 | 3 | 3 | NA | 6 |
| VICTOR | Rofecoxib | 928 | 6 | 3 | 4 | NA | 9 |
| ViP | Placebo | 1102 | 5 | 3 | 3 | 4 | 9 |
| ViP | Rofecoxib | 1099 | 6 | 2 | 1 | 3 | 8 |
| A3191152 | Naproxen | 130 | 0 | 0 | 0 | 0 | 0 |
| A3191152 | Celecoxib | 131 | 0 | 0 | 0 | 0 | 0 |
| SUCCESS-1 (USA/Canada) | Naproxen | 165 | 1 | 2 | 0 | 0 | 3 |
| SUCCESS-1 (USA/Canada) | Celecoxib | 353 | 4 | 2 | 1 | 1 | 4 |
| ADVANTAGE | Naproxen | 526 | 1 | 6 | 0 | 4 | 7 |
| ADVANTAGE | Rofecoxib | 528 | 5 | 1 | 4 | 5 | 10 |
| VIGOR | Naproxen | 2008 | 4 | 9 | 7 | 15 | 17 |
| VIGOR | Rofecoxib | 2007 | 20 | 11 | 9 | 22 | 34 |
| TARGET (0117) | Naproxen | 4156 | 7 | 13 | 8 | 11 | 27 |
| TARGET (0117) | Lumiracoxib | 4197 | 15 | 17 | 11 | 14 | 40 |
| CLASS (N49-98-02-035) | Ibuprofen | 1123 | 9 | 6 | 6 | 8 | 17 |
| CLASS (N49-98-02-035) | Celecoxib | 1184 | 9 | 2 | 6 | 9 | 13 |
| TARGET (2332) | Ibuprofen | 3709 | 5 | 9 | 10 | 15 | 23 |
| TARGET (2332) | Lumiracoxib | 3795 | 5 | 8 | 8 | 13 | 19 |
| CAESAR | Diclofenac | 432 | 5 | 5 | 4 | 5 | 12 |
| CAESAR | Celecoxib | 415 | 4 | 1 | 5 | 6 | 8 |
| CLASS (N49-98-02-102) | Diclofenac | 1081 | 5 | 6 | 7 | 9 | 16 |
| CLASS (N49-98-02-102) | Celecoxib | 1136 | 10 | 2 | 6 | 10 | 17 |
| Emery 1999 | Diclofenac | 125 | 0 | 0 | 0 | 0 | 0 |
| Emery 1999 | Celecoxib | 133 | 1 | 0 | 0 | 1 | 1 |
| SUCCESS-1 (World) | Diclofenac | 745 | 0 | 4 | 4 | 5 | 4 |
| SUCCESS-1 (World) | Celecoxib | 1472 | 6 | 6 | 1 | 4 | 12 |
| EDGE | Diclofenac | 2607 | 11 | 6 | 4 | 8 | 12 |
| EDGE | Etoricoxib | 2789 | 19 | 4 | 5 | 10 | 25 |
| EDGE II | Diclofenac | 3251 | 25 | 12 | 7 | 18 | 42 |
| EDGE II | Etoricoxib | 3266 | 14 | 9 | 7 | 24 | 30 |
| MEDAL | Diclofenac | 19 103 | 88 | 42 | 38 | 105 | 149 |
| MEDAL | Etoricoxib | 19 970 | 84 | 48 | 39 | 95 | 154 |
| Cannon 2000 | Diclofenac | 256 | 1 | 1 | 2 | 2 | 4 |
| Cannon 2000 | Rofecoxib | 494 | 2 | 0 | 1 | 1 | 3 |
| Saag 2000 | Diclofenac | 219 | 1 | 1 | 2 | 4 | 2 |
| Saag 2000 | Rofecoxib | 443 | 2 | 1 | 0 | 0 | 3 |
| Fleischmann 2003 | Celecoxib | 99 | 0 | 0 | 0 | 0 | 0 |
| Fleischmann 2003 | Lumiracoxib | 207 | 2 | 0 | 0 | 0 | 2 |
| Tannenbaum 2004 | Celecoxib | 110 | 0 | 0 | 0 | 0 | NA |
| Tannenbaum 2004 | Lumiracoxib | 225 | 1 | 0 | 0 | 0 | NA |
| Overall | 117 218 | 554 | 377 | 312 | 676 | 1091 |
APTC=Antiplatelet Trialists’ Collaboration; NA=not available. See web extra appendix 3 for full names of trials.
*Slightly different numbers of patient years might be used for analysis of each outcome but only number of patient years for primary outcome “incidence of myocardial infarction” is provided here.
†Includes fatal and non-fatal events.
‡Death from any cause.